Exelixis, Inc. (EXEL)
NASDAQ: EXEL · Real-Time Price · USD
51.29
+1.83 (3.70%)
At close: May 13, 2026, 4:00 PM EDT
51.50
+0.21 (0.41%)
After-hours: May 13, 2026, 7:57 PM EDT
Exelixis Employees
Exelixis had 1,077 employees as of December 31, 2025. The number of employees decreased by 70 or -6.10% compared to the previous year.
Employees
1,077
Change (1Y)
-70
Growth (1Y)
-6.10%
Revenue / Employee
$2,205,656
Profits / Employee
$773,836
Market Cap
12.89B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 1,077 | -70 | -6.10% |
| Dec 31, 2024 | 1,147 | -163 | -12.44% |
| Dec 31, 2023 | 1,310 | 87 | 7.11% |
| Dec 31, 2022 | 1,223 | 269 | 28.20% |
| Dec 31, 2021 | 954 | 181 | 23.42% |
| Dec 31, 2020 | 773 | 156 | 25.28% |
| Dec 31, 2019 | 617 | 133 | 27.48% |
| Dec 31, 2018 | 484 | 112 | 30.11% |
| Dec 31, 2017 | 372 | 85 | 29.62% |
| Dec 31, 2016 | 287 | 172 | 149.57% |
| Dec 31, 2015 | 115 | 17 | 17.35% |
| Dec 31, 2014 | 98 | -129 | -56.83% |
| Dec 31, 2013 | 227 | 53 | 30.46% |
| Dec 31, 2012 | 174 | -26 | -13.00% |
| Dec 31, 2011 | 200 | -183 | -47.78% |
| Dec 31, 2010 | 383 | -293 | -43.34% |
| Dec 31, 2009 | 676 | 0 | - |
| Dec 31, 2008 | 676 | -59 | -8.03% |
| Dec 31, 2007 | 735 | 84 | 12.90% |
| Dec 31, 2006 | 651 | 101 | 18.36% |
| Dec 31, 2005 | 550 | 33 | 6.38% |
| Dec 31, 2004 | 517 | -56 | -9.77% |
| Dec 31, 2003 | 573 | 23 | 4.18% |
| Dec 31, 2002 | 550 | -21 | -3.68% |
| Dec 31, 2001 | 571 | 214 | 59.94% |
| Dec 31, 2000 | 357 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
| Company Name | Employees |
|---|---|
| BioMarin Pharmaceutical | 3,221 |
| Genmab | 3,088 |
| Jazz Pharmaceuticals | 2,890 |
| Ionis Pharmaceuticals | 1,402 |
| Axsome Therapeutics | 1,220 |
| Ascendis Pharma | 1,189 |
| Madrigal Pharmaceuticals | 915 |
| BridgeBio Pharma | 839 |
EXEL News
- 1 day ago - Exelixis Transcript: Bank of America Global Healthcare Conference 2026 - Transcripts
- 6 days ago - Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in May - Business Wire
- 6 days ago - Exelixis price target raised to $56 from $54 at H.C. Wainwright - TheFly
- 6 days ago - Exelixis price target raised to $50 from $49 at Morgan Stanley - TheFly
- 6 days ago - Exelixis price target raised to $47 from $44 at Stifel - TheFly
- 6 days ago - Exelixis price target raised to $55 from $51 at TD Cowen - TheFly
- 8 days ago - Exelixis Earnings Call Transcript: Q1 2026 - Transcripts
- 8 days ago - Exelixis Announces First Quarter 2026 Financial Results and Provides Corporate Update - Business Wire